Evofem Biosciences to Present at RBC Global Healthcare Conference

SAN DIEGO, Feb. 16, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that Saundra Pelletier, CEO, will present at the 2018 RBC Capital Markets Global Healthcare Conference as follows:

The presentation will be webcast live at the aforementioned time via the Company's website at www.evofem.com under the "Investors" section.

Evofem's lead product candidate, Amphora^® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel, is being studied as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs).  The Company completed enrollment ahead of schedule in its confirmatory Phase 3 clinical trial of Amphora for contraception, and expects to report study data in the first quarter of 2019.  Recruitment is ongoing in a Phase 2b/3 clinical trial of Amphora to prevent urogenital chlamydia and gonorrhea in women.   

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a biotechnology company that develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. For more information regarding Evofem, visit www.evofem.com.

Forward-Looking Statements

Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the results of the Phase 3 contraceptive clinical trial and any expected completion date for this clinical trial as well as statements about the results of the Phase 2b/3 STI clinical trial and any expected completion date for this clinical trial.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Evofem will be able to raise the additional funding necessary to complete its clinical trials, including the Phase 3 contraceptive clinical trial of Amphora and the Phase 2b/3 STI clinical trial; whether Evofem's product candidates will advance through the clinical trial process on a timely basis, according to presently contemplated schedules or at all; whether Evofem's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed and other factors discussed in the "Risk Factors-Risks Related to Evofem" section of a registration statement on Form S-4 initially filed with the Securities and Exchange Commission (the SEC) by Evofem Biosciences, Inc. (formerly known as Neothetics, Inc.) on November 15, 2017, a copy of which is available on the Evofem website. In addition, the forward-looking statements included in this press release represent Evofem's views as of the date hereof. Evofem anticipates that subsequent events and developments will cause its views to change. However, while Evofem may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Evofem's views as of any date subsequent to the date hereof.

Evofem Biosciences' Contact
Amy Raskopf
Investor Relations
[email protected]
858-550-1900 x167

SOURCE Evofem Biosciences, Inc.

Related Links

http://www.evofem.com